| Identification | Back Directory | [Name]
2,4-Pyrimidinediamine, 5-chloro-N2-[2,3-dihydro-7-methyl-8-(4-piperidinyl)-1,4-benzodioxin-5-yl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- | [CAS]
1893419-37-8 | [Synonyms]
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(7-methyl-8-(piperidin-4-yl)-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)pyrimidine-2,4-diamine
2,4-Pyrimidinediamine, 5-chloro-N2-[2,3-dihydro-7-methyl-8-(4-piperidinyl)-1,4-benzodioxin-5-yl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]- | [Molecular Formula]
C27H32ClN5O4S | [MOL File]
1893419-37-8.mol | [Molecular Weight]
558.09 |
| Hazard Information | Back Directory | [Uses]
Dirozalkib (Compound 4) is the inhibitor for ALK with an IC50 of 0.9 nM. Dirozalkib exhibits anti-proliferative activity in cancer cells NCI-H3122, Karpas-299 and NCI-H2228 with IC50s of 130.4, 0.71 and 15.11 nM, respectively. Dirozalkib exhibits good pharmacokinetics characteristics with an bioavailbility of 30%~50%[1]. | [References]
[1] Wu Y, et al., Polycyclic anaplastic lymphoma kinase inhibitor. WO2016050171 |
|
|